July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Eytan Ruppin: We present IRIS: a machine-learning method aimed at identifying candidate ligand-receptor interactions that are likely to mediate immune checkpoint blockade resistance in the tumor microenvironment.
Sep 24, 2023, 18:21

Eytan Ruppin: We present IRIS: a machine-learning method aimed at identifying candidate ligand-receptor interactions that are likely to mediate immune checkpoint blockade resistance in the tumor microenvironment.

Quoting Eytan Ruppin, Chief at the Cancer Data Science Lab of the National Institute of Health (NIH), on X/Twitter:

“Happy to share our recent work out on bioRxiv. We present IRIS: a machine-learning method aimed at identifying candidate ligand-receptor interactions that are likely to mediate immune checkpoint blockade (ICB) resistance in the tumor microenvironment.

IRIS takes as input: 1) ligand-receptor interaction activity profiles for each tumor sample, inferred from bulk transcriptomics harnessing our previously published tools CODEFACS and LIRICS and 2) the corresponding ICB response label for each sample.

IRIS then employs a two-step supervised machine learning method to identify a set of resistance activated (RAIs) and resistance deactivated interactions (RDIs), which are inferred to lead to ICB resistance. We applied IRIS to the 5 largest melanoma bulk RNA-seq ICB cohorts.

Image

Strikingly, we found that the activity of deactivated interactions (RDI/RDS) offer markedly stronger predictive value for ICB therapy response compared to activated ones.

Image

Moreover, our inferred RDIs (RDS) predictive accuracy is superior to that of state-of-the-art published transcriptomics biomarkers across an array of melanoma bulk RNA-seq ICB cohorts.

Image

Focusing on resistance deactivated interactions, we find that many of these interactions are involved in stimulatory chemokine signaling, and that their activity is correlated with both CD8+ T cell infiltration levels and enriched in “hot” (brisk) tumor niches in TCGA melanoma.

Image

Taken together, this study proposes a new strongly predictive immunotherapy response biomarker, showing that following ICB treatment, resistant tumors inhibit lymphocyte infiltration by deactivating specific key ligand-receptor interactions.

Image

This work was led by Sahil Sahni and Kun Wang. We thank all the co-authors for their support!”

For details, click here.
Source: Eytan Ruppin/Twitter